DESCRIPTION: Emerging viral diseases sometimes arise when viruses mutate to
acquire the ability to infect cells of a new species. Coronaviruses
generally cause disease in only one animal species. The viruses are readily
transmitted to other members of the same species, but they are transmitte
poorly or not at all to other species. This species specificity of
coronavirus infection and disease is determined in part by species-specific
differences among the cell membrane glycoproteins that coronaviruses use as
receptors to enter susceptible host cells. Receptors for mouse, human, pig,
dog and cat coronaviruses have been identified and their cDNAs cloned. When
the recombinant receptor proteins are expressed in virus-resistant cell
lines, they become susceptible to infection with the appropriate
coronavirus. Rarely, host range mutants of viruses occur that have gained
the ability to infect cells from another animal species. Because not only
the major receptor but a large number of alternative receptors for murine
coronaviruse MHV have been identified and host range mutants of the virus
have been selected, this is an excellent model system for the study of how
mutations that affect virus species specificity may be selected. The
proposed experiments will examine how murine coronaviruses acquire the
ability to infect cells from many other species, and determine whether such
host range mutants can infect the new species in vivo and cause disease.
The hypothesis that host range mutants of viruses are selected in cells or
tissues that express low levels of the natural virus receptor in addition to
alternative receptors of lower efficiency will be tested. Using a
combination of genetic, biochemical, and molecular techniques with reagents
that have been developed to study MHV receptors, mutations will be
identified in the virus attachment glycoprotein that affect receptor
specificity and identify what receptors these mutant viruses use to infect
cells of a different species. The molecular mechanism by which expression
of viru receptors is down-regulated in persistently infected cells will also
be studied.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
041096314
UEI
MW8JHK6ZYEX8
Project Start Date
01-February-1988
Project End Date
30-June-2003
Budget Start Date
01-July-2000
Budget End Date
30-June-2001
Project Funding Information for 2000
Total Funding
$331,643
Direct Costs
$222,020
Indirect Costs
$109,623
Year
Funding IC
FY Total Cost by IC
2000
National Institute of Allergy and Infectious Diseases
$331,643
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI025231-13
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI025231-13
Patents
No Patents information available for 5R01AI025231-13
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI025231-13
Clinical Studies
No Clinical Studies information available for 5R01AI025231-13
News and More
Related News Releases
No news release information available for 5R01AI025231-13
History
No Historical information available for 5R01AI025231-13
Similar Projects
No Similar Projects information available for 5R01AI025231-13